NutraGenesis, LLC revealed the publication of two new studies on Orisett, which demonstrate the ingredient’s ability to provide glucose management support.
 
Orisett is a naturally derived, patent-pending nutraceutical designed to define the benchmark for the glucose management category. Containing low molecular weight chitosan oligosaccharide bioactives derived from crab shells, clinically tested Orisett helps promote both long-term blood sugar maintenance as well as short-term post-prandial responses via multiple mechanisms of action.
 
In the first study published in the peer reviewed journal Food Science and Biotechnology, researchers evaluated Orisett’s fast-acting properties and ability to control carbohydrates via alpha-glucosidase inhibition in a short-term, crossover, placebo-controlled human clinical trial involving 13 healthy subjects.
 
Alpha-glucosidase is an enzyme that digests sucrose and starch-derived sugar. This study found that consumption of a single 500 mg dose of Orisett followed by 75 mg of sucrose (administered using an Oral Sucrose Tolerance Test) resulted in significant reductions in post-meal blood sugar levels as well as an overall delay in absorption of glucose from the digestive system.
 
These results confirm previous pre-clinical studies using animal models that also illustrated Orisett’s ability to help maintain a healthy blood sugar response as a result of its superior alpha-glucosidase enzyme-inhibiting, carb control properties.
 
In a second, 12-week study published in the peer-reviewed journal Food and Function, researchers found that Orisett reduced both long‐term blood glucose and post-prandial blood glucose levels in a randomized, double-blind, placebo-controlled human clinical trial.
 
Fifty-one healthy subjects took 500 mg of either Orisett or placebo three times daily for 12 weeks. After a 12-hour washout period at the end of the study, post-prandial blood sugar was evaluated by giving subjects 75g of glucose using an Oral Glucose Tolerance Test (OGTT). Compared to Week 0 results, post-meal blood sugar levels in Orisett subjects at Week 12 were significantly reduced. Subjects taking Orisett also had a significant increase in levels of
adiponectin.
 
Both human clinical trials demonstrated that Orisett is highly bioavailable and well tolerated. Additionally, a glycosylated hemoglobin (HbA1c) test was performed at the end of the trial which demonstrated a  significant reduction in HbA1c after 12 weeks.
 
For more information: www.nutragenesis.com